Deals Shaping the Medical Industry, July 2019
Executive Summary
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June 2019.
You may also be interested in...
Asia Deal Watch: BeiGene Gets Chinese Rights To Two EUSA Rare Disease Therapies
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
2019 India Deals - Sell, License, Brands And China
Scrip highlights the key transactions involving Indian firms in 2019. Divestments and licensing were among the prominent themes that dotted the deal landscape in the year gone by.
Deals in Depth July 2023
Eight $1bn+ alliances were penned in July. Topping the list was a potential $2.8bn deal under which Alnylam granted Roche exclusive global rights outside the US to develop and commercialize its Phase II hypertension candidate zilebesiran. The companies will co-develop zilebesiran in the US.